Skip to main content
Publications
Kirkeleit J, Riise T, Wielscher M, Accordini S, Carsin AE, Dratva J, Franklin KA, Garcia-Aymerich J, Jarvis D, Leynaert B, Lodge CJ, Real FG, Schlunssen V, Corsico AG, Heinrich J, Holm M, Janson C, Benediktsdottir B, Jogi R, Dharmage SC, Jarvelin MR, Svanes C. Early life exposures contributing to accelerated lung function decline in adulthood - a follow-up study of 11,000 adults from the general population. EClinicalMedicine. 2023 Dec 8;66:102339. doi: 10.1016/j.eclinm.2023.102339
Aparicio J, Virgili Manrique AC, Capdevila J, Munoz Boza F, Galvan P, Richart P, Oliveres H, Paez D, Hernando J, Serrano S, Vera R, Hernandez‑Yague X, Gallego RA, Riesco‑Martinez MC, Garcia de Albeniz Martinez X, Maurel J. Randomized phase II trial of FOLFIRI‑panitumumab compared with FOLFIRI alone in patients with RAS wild‑type circulating tumor DNA metastatic colorectal cancer beyond progression to first‑line FOLFOX‑panitumumab: the BEYOND study (GEMCAD 17‑01). Clin Trans Oncol. 2022 Nov;24(11):2155-65. doi: 10.1007/s12094-022-02868-x
McSweeney L, Breckons M, Fattakhova G, Oluboyede Y, Vale L, Ternent L, Balp M-M, Doward L, Brass CA, Beyer F, Sanyal A, Anstee QM. Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis. JHEP Rep. 2020 Mar 6;2(3). doi: 10.1016/j.jhepr.2020.100099